Crohn's patients continue therapy longer than ulcerative colitis patients

10/16/2013 | MedPage Today (free registration)

Therapy with the anti-tumor necrosis factor drug infliximab was significantly longer in Crohn's disease patients than in those with ulcerative colitis, according to a study presented at a meeting of the American College of Gastroenterology. The Crohn's disease group had a greater time to treatment failure, time to first dose escalation and time to switch to another agent compared with ulcerative colitis patients. Providers should take this difference "into account when considering use of infliximab in patients with ulcerative colitis," a researcher said.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA